Qin Ouyang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qin Ouyang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Bing Wang
Institute of Microcirculation, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China
1 shared publication - Bingwei Li
Institute of Microcirculation, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China
1 shared publication - Mingming Liu
Institute of Microcirculation, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China
1 shared publication - Ruijuan Xiu
Institute of Microcirculation, Chinese Academy of Medical Sciences & Peking Union Medical College
1 shared publication - Weiqi Liu
Institute of Microcirculation, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China
1 shared publication - Xiang Xu
Institute of Microcirculation, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China
1 shared publication
Latest Publications
- Open Access
- 20 March 2026
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 30 (6) , e71098
Consequences of CRISPR ‐Cas9‐Mediated Stromelysin‐1 Knockout in Pancreatic Islet Microvascular Endothelial Cells
The integrity of the pancreatic islet microvasculature is critical for endocrine function, yet it is progressively compromised by glucotoxicity in diabetes. While matrix metalloproteinases are implicated, the role of stromelysin‐1 as a potential upstream driver of endothelial dysfunction remains poorly defined. The aim of our study was to elucidate the role of stromelysin‐1 in mediating glucotoxic injury to islet microvascular endothelial cells (IMECs). To this end, we employed a CRISPR/Cas9‐mediated knockout of stromelysin‐1 in IMECs. Cellular functions, including proliferation, migration, and angiogenesis, were assessed using IncuCyte ZOOM live‐cell imaging, while endothelial barrier integrity was quantified via a 40 kDa dextran flux assay. Additionally, the secretome was profiled using a cytokine antibody array. We found that genetic ablation of stromelysin‐1 conferred protection against glucotoxicity. Stromelysin‐1 KO IMECs exhibited significantly enhanced proliferation, migration, and angiogenic capacity compared to wild‐type controls. Furthermore, stromelysin‐1 deficiency restored endothelial monolayer integrity by attenuating high‐glucose‐induced hyperpermeability. These functional improvements were linked to a remodelling of the secretome, characterised by decreased secretion of the pro‐degradative MMP‐2 and increased secretion of the anti‐inflammatory cytokine IL‐10 and the endogenous inhibitor TIMP‐2. Overall, our findings establish stromelysin‐1 as a crucial mediator of glucotoxic injury in islet microvascular endothelial cells.
- 20 March 2026
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 30 (6) , e71098
Open AccessConsequences of CRISPR ‐Cas9‐Mediated Stromelysin‐1 Knockout in Pancreatic Islet Microvascular Endothelial Cells
The integrity of the pancreatic islet microvasculature is critical for endocrine function, yet it is progressively compromised by glucotoxicity in diabetes. While matrix metalloproteinases are implicated, the role of stromelysin‐1 as a potential upstream driver of endothelial dysfunction remains poorly defined. The aim of our study was to elucidate the role of stromelysin‐1 in mediating glucotoxic injury to islet microvascular endothelial cells (IMECs). To this end, we employed a CRISPR/Cas9‐mediated knockout of stromelysin‐1 in IMECs. Cellular functions, including proliferation, migration, and angiogenesis, were assessed using IncuCyte ZOOM live‐cell imaging, while endothelial barrier integrity was quantified via a 40 kDa dextran flux assay. Additionally, the secretome was profiled using a cytokine antibody array. We found that genetic ablation of stromelysin‐1 conferred protection against glucotoxicity. Stromelysin‐1 KO IMECs exhibited significantly enhanced proliferation, migration, and angiogenic capacity compared to wild‐type controls. Furthermore, stromelysin‐1 deficiency restored endothelial monolayer integrity by attenuating high‐glucose‐induced hyperpermeability. These functional improvements were linked to a remodelling of the secretome, characterised by decreased secretion of the pro‐degradative MMP‐2 and increased secretion of the anti‐inflammatory cytokine IL‐10 and the endogenous inhibitor TIMP‐2. Overall, our findings establish stromelysin‐1 as a crucial mediator of glucotoxic injury in islet microvascular endothelial cells.